Evidence map›Paper›PMID 28146436›Full record

ArticleOncotarget2017

Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance.

Chao Shang, Lin Sun, Jiale Zhang, Bochao Zhao, Xiuxiu Chen, Huimian Xu, Baojun Huang

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Non-coding RNAs underlying chemoresistance in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020
    Review
  17. Review
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chao ShangDepartment of Neurobiology, College of Basic Medicine, China Medical University, Shenyang, 110001, China.
Lin SunDepartment of Gastrointestinal Surgery, Dalian Municipal Central Hospital, Dalian, 116033, China.
Jiale ZhangDepartment of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, 110004, China.
Bochao ZhaoDepartment of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, 110004, China.
Xiuxiu ChenDepartment of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, 110004, China.
Huimian XuDepartment of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, 110004, China.
Baojun HuangDepartment of Surgical Oncology, First Affiliated Hospital, China Medical University, Shenyang, 110004, China.
China Medical University · CNDalian Municipal Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer Susceptibility Candidate 9 (CASC9) is a novel gene generating long non-coding RNA (lncRNA) with oncogenic potential that was first identified in esophageal cancer. In this study, we have found that CASC9 was overexpressed in gastric cancer (GC) compared to normal gastric tissue. A higher expression level was associated with aggressive pathological characteristics, including deep invasion, poor differentiation and lymph node metastases. In two gastric cancer cell lines, BGC823 and SGC7901, CASC9 were both overexpressed compared to that of normal gastric epithelial cell (GES-1). Moreover, the expression of CASC9 was even higher in BGC823/DR and SGC7901/DR cells that are resistant to paclitaxel or adriamycin. CASC9 knockdown inhibited proliferation and promoted cell apoptosis In BGC823/DR and SGC7901/DR cells. The invasion potential was also significantly inhibited measured by Transwell assay. In addition, CASC9 knockdown in BGC823/DR and SGC7901/DR cells restored chemosensitivity to paclitaxel and adriamycin. This was associated with decreased expression of multidrug resistance 1 (MDR1) protein. Taken together, our data suggest that expression of lncRNA CASC9 correlated with aggressive pathological characteristics of GC, it may serve as a potential oncogene to regulate proliferation, invasion, and chemoresistance of GC cells.

Indexed as

Gene SilencingApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Cell LineCell Line, TumorCell MovementCell ProliferationDoxorubicinDrug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansPaclitaxelReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingATP Binding Cassette Transporter, Subfamily B, Member 1Doxorubicinlong noncoding RNA CASC9, humanPaclitaxelRNA, Long NoncodingCASC9chemotherapy resistancegastric cancerlong noncoding RNAmalignancy

Identifiers

PMID28146436
PMCPMC5362493
OpenAlexW2581213959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.